The facial skin is thin and more susceptible to steroid-induced thinning. Short, intermittent courses may be prescribed, but routine facial use should only be under medical supervision.
Most patients notice reduced redness and itching within 2-3 days. If there is no improvement after 5-7 days, contact your clinician for reassessment.
Both deliver the same 2 %/0.12 % concentrations, but the tube often contains a slightly thicker base that may feel less greasy. The active ingredients and clinical effect are equivalent.
A new rash could indicate an allergic reaction or secondary infection. Discontinue use and seek medical advice promptly.
Occlusion dramatically increases steroid absorption and should only be used if specifically advised by a healthcare professional.
Use in children under 12 is generally discouraged unless a specialist determines that the benefits outweigh the risks, owing to higher susceptibility to systemic absorption.
Topical corticosteroids can raise blood glucose in susceptible individuals when large areas are treated or used for prolonged periods. Monitor blood sugar if you have diabetes and notice changes.
Resistance to fusidic acid can develop, especially with prolonged or inappropriate use. Adhering to the prescribed duration helps minimise this risk.
Gentle shaving is permissible, but avoid irritating the skin. Apply the cream after shaving and allow the skin to dry before dressing.
The combination adds antibacterial protection, which can be advantageous when a bacterial infection co-exists. Pure betamethasone lacks this antimicrobial action and may require a separate antibiotic if infection is present.
Active ingredients: Betamethasone valerate 2 % + Fusidic acid 0.12 % Formulation: Topical cream/ointment supplied in a tube Therapeutic class: Dermatological corticosteroid-antibiotic combination (Skin Care) Regulatory status in the UK: Prescription-only medicine (POM) approved by the Medicines and Healthcare products Regulatory Agency (MHRA)
Betamethasone valerate is a potent synthetic glucocorticoid. It binds to intracellular glucocorticoid receptors, altering gene transcription to suppress the release of inflammatory mediators (e.g., prostaglandins, cytokines). This reduces redness, swelling, and itching.
Fusidic acid is a steroidal antibiotic that targets bacterial protein synthesis. It binds to elongation factor G (EF-G) on the ribosome, preventing translocation of the growing peptide chain and thereby inhibiting growth of susceptible Gram-positive bacteria, especially Staphylococcus aureus.
The combination delivers dual action: rapid anti-inflammatory effect from the corticosteroid and localized antibacterial activity from fusidic acid, making it useful for inflamed skin that is infected or at high risk of infection.
These indications follow the product’s Summary of Product Characteristics (SPC) and the British National Formulary (BNF) for the UK.
Who should use this medication?
Absolute contraindications
Relative contraindications / cautions
Standard regimen: Apply a thin layer to the affected skin 2-3 times daily (usually morning and evening).
Duration: Generally up to 2 weeks or as directed by a clinician. Do not exceed the prescribed course without medical review.
Application tips:
Wash and gently pat the area dry before use.
Use a fingertip amount; spreading a larger amount does not increase efficacy and raises the risk of side effects.
Avoid contact with eyes, mucous membranes, and broken skin unless the infection is present there and the clinician advises it.
Missed dose: Apply as soon as remembered unless it is near the time of the next scheduled dose; do not double the amount.
Overdose: Excessive application can lead to systemic corticosteroid effects (e.g., Cushingoid features, adrenal suppression). Seek medical attention if signs such as unexplained weight gain, facial rounding, or prolonged fatigue appear.
Discontinuation: For short courses, abrupt cessation is usually safe. If the product has been used for longer than 2 weeks, a tapering plan (gradually reducing frequency) may be advised to avoid rebound inflammation.
This article provides educational information about Betamethasone and Fusidic Acid and is not a substitute for professional medical advice. Treatment decisions, including the use of this product for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
